BackTable Tumor Board
BackTable Tumor Board
Podcast Description
BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care. Season One features in-depth conversations on the topic of Hepatocellular Carcinoma (HCC) provided by a group of medical oncologists, interventional radiologists, hepatobiliary surgeons, hepatologists, and patient coordinators. Stay tuned for the next season!
Podcast Insights
Content Themes
The podcast explores various aspects of hepatocellular carcinoma, including treatment options, complex case discussions from tumor board meetings, and insights on the role of surgery, interventional oncology, and transplantation. Episodes feature detailed case reviews, such as the principles of practice in HCC tumor boards and tips for starting a career in interventional oncology.
BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care.
Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes.
—
Get the BackTable app
https://www.backtable.com/app
—
This podcast is supported by an educational grant from Johnson & Johnson.
—
Timestamps
00:00 – Introduction
01:02 – Risk Stratification
07:22 – Upstaging to High Risk
10:06 – Calculators and Patient Education
15:22 – Specific Tests Use Cases
18:50 – Conflicting Biomarker Results
21:36 – Adjunct Tests and Counseling
24:03 – Recurrence After Chemo Next Steps
27:01 – Escalation Deescalation Balance
32:48 – Future Research Priorities
35:43 – Biology Based Risk Stratification
38:03 – Clinical Pearls and Wrap Up
—
More about this episode
The conversation highlights the heterogeneity of intermediate-risk disease, the role and importance of expert pathology over-reads, and the need to accurately document the risk category for ongoing care. They discuss selective use of urinary and genomic assays and how these tests fit alongside cystoscopy and blue light endoscopy. Practical treatment approaches are reviewed, including when to use intravesical gemcitabine or BCG, managing care during BCG shortages, and balancing escalation versus de-escalation of therapy. Additional topics include strategies for long-term surveillance, upper tract imaging, rising rates of bladder cancer in younger patients, and why thorough TURBT and strong patient-provider communication remain central to optimal management.
—
Resources
The Memorial Study
https://www.mskcc.org/cancer-care/clinical-trials/19-288
The BRIDGE Study
https://www.nejm.org/doi/full/10.1056/NEJMoa1501035
—
BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.